Department of Biochemistry and Molecular Biology.
Department of Molecular Pharmacology and Experimental Therapeutics, and.
J Clin Invest. 2018 Apr 2;128(4):1217-1228. doi: 10.1172/JCI95146.
Cellular senescence, a major tumor-suppressive cell fate, has emerged from humble beginnings as an in vitro phenomenon into recognition as a fundamental mechanism of aging. In the process, senescent cells have attracted attention as a therapeutic target for age-related diseases, including cardiovascular disease (CVD), the leading cause of morbidity and mortality in the elderly. Given the aging global population and the inadequacy of current medical management, attenuating the health care burden of CVD would be transformative to clinical practice. Here, we review the evidence that cellular senescence drives CVD in a bimodal fashion by both priming the aged cardiovascular system for disease and driving established disease forward. Hence, the growing field of senotherapy (neutralizing senescent cells for therapeutic benefit) is poised to contribute to both prevention and treatment of CVD.
细胞衰老，一种主要的肿瘤抑制性细胞命运，已经从一个简单的体外现象发展成为衰老的基本机制。在这个过程中，衰老细胞作为与年龄相关疾病的治疗靶点引起了人们的关注，包括心血管疾病（CVD），这是老年人发病率和死亡率的主要原因。鉴于全球人口老龄化和当前医疗管理的不足，减轻 CVD 的医疗保健负担将对临床实践产生变革性的影响。在这里，我们回顾了细胞衰老以两种方式驱动 CVD 的证据，既为衰老的心血管系统疾病做好了准备，又推动了已确立的疾病的发展。因此，日益发展的衰老治疗学领域（中和衰老细胞以获得治疗益处）有望为 CVD 的预防和治疗做出贡献。
